KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Receivables - Other (2016 - 2025)

Historic Receivables - Other for Fulgent Genetics (FLGT) over the last 10 years, with Q3 2025 value amounting to $1.4 million.

  • Fulgent Genetics' Receivables - Other rose 1039.37% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 1039.37%. This contributed to the annual value of $1.8 million for FY2024, which is 3404.09% up from last year.
  • Latest data reveals that Fulgent Genetics reported Receivables - Other of $1.4 million as of Q3 2025, which was up 1039.37% from $2.1 million recorded in Q2 2025.
  • Fulgent Genetics' 5-year Receivables - Other high stood at $19.8 million for Q4 2022, and its period low was $506000.0 during Q1 2021.
  • Its 5-year average for Receivables - Other is $2.4 million, with a median of $1.4 million in 2022.
  • As far as peak fluctuations go, Fulgent Genetics' Receivables - Other surged by 131382.75% in 2022, and later plummeted by 9335.05% in 2023.
  • Over the past 5 years, Fulgent Genetics' Receivables - Other (Quarter) stood at $1.4 million in 2021, then surged by 1313.83% to $19.8 million in 2022, then crashed by 93.35% to $1.3 million in 2023, then surged by 34.04% to $1.8 million in 2024, then dropped by 20.7% to $1.4 million in 2025.
  • Its Receivables - Other was $1.4 million in Q3 2025, compared to $2.1 million in Q2 2025 and $2.5 million in Q1 2025.